Biocon Limited — Important, 15-12-2024: Updates

Biocon Biologics Ltd (BBL) has secured a significant milestone as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of YESINTEK®, a biosimilar to J&J’s Stelara®. This product is intended for treating plaque psoriasis in adults and children, as well as psoriatic arthritis and Crohn’s disease in adults. Clinical trials have demonstrated that YESINTEK® possesses a comparable pharmacokinetic, safety, efficacy, and immunogenicity profile to the original Stelara®. This positive opinion follows earlier FDA approval in the U.S., enhancing BBL's growth trajectory in the European market. Investors should monitor BBL for potential market entry and revenue generation from YESINTEK®, as it strengthens the company's position in the biosimilars sector.